|
|


|
Download StockRing Free Buy-Sell-Hold iPhone App for 1,200 stocks in Energy Healthcare Finance Services & Tech
|
|
BUY DOW 30+: VFC SYT SPLS RTN NSC ENERGY: XCO VTNR TOT TLLP TGS HEALTH: WX WST WCRX TRIB TECH
FINANCE: WLP SIVB MKL MCY JPM SERVICES: WM WCN WAG TLK SRCL TECH: WDC STX SNPS PAY OTEX SELL DOW 30+: XEL WPZ WMT WLK WAB ENERGY: YZC WMB WLL WFT VNR HEALTH: WOOF WCG VRX VASC VAR
FINANCE: ZION XLI XLB WSH WDR SERVICES: WYNN WMT VZ VTR VOD TECH: YNDX WCC VRSN VMW TXN
Our FREE iPhone App with Buy-Sell-Hold ratings for 1,200 stocks:
iPhone App Buy-Sell-Hold Ratings for 5-5-2013
|
|


|
5/23/2013 Thursday, May 23, 2013 (Irvine, California) Today StockRing.com Recommendation is to "HOLD"for Merck & Compan (NASDAQ:MRK) Stock.
MRK stock opening price was $46.43 per share.
Current price of NASDAQ:MRK Stock is $47.33 per share
and it is
$+0.62, (+1.33%) today
and it was trading in the daily range of $728450 per share.
Current Bid Price for (NASDAQ:MRK) stock is $3.64 and the Ask Price is $47.33. In the last 52 weeks
MRK stock was trading in the range of $37.02 - 48.79. 50-Day Moving Average for (NASDAQ:MRK) stock is
$16.365B and 200-Day Moving Average is $46.39. On average analysts predict that One Year Target Estimated price for
(NASDAQ:MRK) stock is $44.04.
Merck & Compan (NASDAQ:MRK) is rated as a wait on 5/23/2013 10:56:49 AM.
Merck & Compan (NASDAQ:MRK) Market capitalization is $142.9B. (NASDAQ:MRK) stock average daily volume is
N/A shares per day.
However, on last trading session of 4:00pm, 2012
MRK stock traded 21,796,608 shares.
Also The Number of days it would take short sellers on average to repurchase all the borrowed shares or Short Ratio for (NASDAQ:MRK) stock is 46.207B.
On previous trading session MRK Stock closed at $46.71 per share.
Last year Merck & Compan (NASDAQ:MRK) before taxes (EBITDA) (ttm) earned $47.34 on total revenue of $2.66.
Earnings Per Share - EPS (ttm) for MRK stock is 1.96.
Also, (NASDAQ:MRK) Stock Price Per Earnings ratio - P/E is 23.83.
Thus, (NASDAQ:MRK) Stock Price/Sales (ttm) ratio is 50.11 and Price/Book (mrq) ratio is 3.05.
(NASDAQ:MRK) Stock pays a dividend of $ " per share which is a yield of "NYSE"%.
So at this time (NASDAQ:MRK) Stock maintains Trailing Annual Dividend Rate at 1.90.
|
StockRing Recommendations for Merck & Compan (NASDAQ:MRK) Stock are updated daily here
http://StockRing.com/sr/Buy-Sell-Hold-Stock-Analysis-Ratings.asp?StockName=MRK
At this time
StockRing recommends to buy LONG positions on many stocks from Dow 30+ stocks that currently have a
BUY or
SUPER BUY rating.
If you decide to take a SHORT position and actually sell some stocks sjort right now - please check the section of Dow 30+ stocks that have
a SELL or
SUPER SELL rating.
If you would like to receive Buy-Sell-Hold ratings for stocks from Energy, Healthcare, Finance, Services & Hi-Tech
sectors on your iPhone, then please
download Buy-Sell-Hold iPhone App here:
|
NASDAQ:MRK Stock Charts: 1d 5d 3m 6m 1y 2y 5y Max
Options More Info
|
5/23/2013
1 Year Stock market price chart for Merck & Compan (NASDAQ:MRK) Stock on Thursday, May 23, 2013
|
| |
| 1 Year MRK |
1 Year Dow Jones |
 |
 |
| 1 Year Nasdaq |
1 Year S&P 500 |
 |
 |
|
|
5/23/2013
5 days Stock market price chart for Merck & Compan (NASDAQ:MRK) Stock on Thursday, May 23, 2013
|
| |
| 5 Days MRK |
5 Days Dow Jones |
 |
 |
| 5 Days Nasdaq |
5 Days S&P 500 |
 |
 |
|
|
|
|
|
EUROs for $1 DOLLAR: 30 days |
 | |
|
NASDAQ:MRK Stock Charts: 1d 5d 3m 6m 1y 2y 5y Max
Options More Info
|
| Last Trade: |
47.33 |
| Trade Time: |
4:00pm |
| Change: |
+0.62, (+1.33%) |
| Prev Close: |
46.71 |
| Open: |
46.43 |
| Bid: |
3.64 |
| Ask: |
1.70 |
| 1y Target Est: |
$44.04 |
| 50-Day Moving Average: |
16.365B |
200-Day Moving Average:
|
46.39 |
| Short Ratio: |
46.207B |
| Trailing Annual Dividend Rate: |
1.90 |
|
| Day's Range: |
728450 |
| 52wk Range: |
37.02 - 48.79 |
| Volume: |
21,796,608 |
| Avg Vol: |
N/A |
| Market Cap: |
142.9B |
| P/E (ttm): |
23.83 |
| EPS (ttm): |
1.96 |
| Div & Yield: |
" ("NYSE"%) |
| Revenue (ttm): |
2.66 |
| Earnings before Tax (EBITDA) (ttm): |
47.34 |
| Price/Sales (ttm): |
50.11 |
| Price/Book (mrq): |
3.05 |
|


MERCK CO INC(NYSE: MRK) Company Information
Merck & Co. Inc.
PO Box 100
One Merck Drive
Whitehouse Station, NJ 08889-0100
United States - Map
Phone: 908-423-1000
Fax: 908-735-1253
Web Site: http://www.merck.com
MERCK CO INC(NYSE: MRK) DETAILS
MERCK CO INC(NYSE: MRK) Index Membership: Dow Jones Composite
Dow Industrials
S&P 100
S&P 500
S&P 1500 Super Comp
MERCK CO INC(NYSE: MRK) Sector: Healthcare
MERCK CO INC(NYSE: MRK) Industry: Drug Manufacturers - Major
MERCK CO INC(NYSE: MRK) Full Time Employees: 52,700
MERCK CO INC(NYSE: MRK) BUSINESS SUMMARY
Merck & Co., Inc. provides products for human and animal health in the United States and internationally. The company?s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting. Merck & Co.?s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; and Addex Pharmaceuticals Ltd. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
MERCK CO INC(NYSE: MRK) KEY EXECUTIVES
Mr. Richard T. Clark , 63
Exec. Chairman, Chief Exec. Officer and Pres $ 4.03M $ 0
Mr. Peter N. Kellogg , 52
Chief Financial Officer and Exec. VP $ 1.60M $ 0
Mr. Kenneth C. Frazier , 54
Exec. VP and Pres of Global Human Health $ 2.00M $ 0
Dr. Peter Kim Ph.D., 50
Exec. VP and Pres of Merck Research Laboratories $ 1.91M $ 0
Mr. Bruce N. Kuhlik , 52
Exec. Vice president and Gen. Counsel $ 1.25M $ 0
|
Hedge Funds Are Dumping Merck & Co., Inc. (MRK)
Insider Monkey (blog) - 1 hour ago
Merck & Co., Inc. (NYSE:MRK) was in 56 hedge funds' portfolio at the end of March. MRK investors should pay attention to a decrease in hedge fund sentiment of late.
|
|
Merck Stock: Not a Safe Pick for Dividend InvestorsMotley FoolBig pharma isn't the first industry many investors envision when dreaming of the big profits to be made from health care stocks. While blockbuster drugs can propel the top big pharma companies to massive profits, these broad behemoths can't match the ... |
|
1 Potential Roadblock for the Merck Stock Run-upMotley FoolWhile there are several potential roadblocks for sustained stock success, probably the most likely to make a difference in the coming months is a failure in Merck's pipeline. Another experience like Merck had with Tredaptive could easily stop the stock ...and more » |
|
Early Movers: TGT, LOW, MRK, SPLS & MoreCNBC.com (blog)Merck — Merck announced a $5 billion accelerated share repurchase program. The drug maker will buy back nearly 100 million shares from Goldman Sachs at current market prices. Sony —Sony has cut sales targets for digital cameras, smartphones, and ... |
|
|
| |
|
|
Copyright
© 2012 StockRing.com. All rights reserved. Subscriber Agreement Privacy Agreement Stocks MutualFunds
Data and information is provided for informational purposes only, and is not intended
for trading purposes. Neither StockRing.com nor its partners shall be liable for any errors or delays in the content, or for any
actions taken in reliance thereon. By accessing the StockRing site, a user agrees not to redistribute the information
found therein.
|
| |